Health economic analyses of latent tuberculosis infection screening and preventive treatment among people living with HIV in lower tuberculosis incidence settings: a systematic review [version 1; peer review: awaiting peer review]

Rebecca F. Baggaley¹, Carolin Vegvari², Christian A. Dimala³, Marc Lipman³,⁴, Robert F. Miller⁴, James Brown⁴, Svetlana Degtyareva⁵, Helena A. White⁶, T. Déirdre Hollingsworth⁷, Manish Pareek¹,⁶

¹Department of Respiratory Sciences, University of Leicester, Leicester, LE1 7RH, UK
²Department of Infectious Disease Epidemiology, Imperial College London, London, UK
³UCL Respiratory, University College London, London, UK
⁴Royal Free London National Health Service Foundation Trust, London, UK
⁵RUDN University, Moscow, Russian Federation
⁶Department of Infection and HIV Medicine, University Hospitals of Leicester NHS Trust, Leicester, UK
⁷Big Data Institute, University of Oxford, Oxford, UK

Abstract

Introduction: In lower tuberculosis (TB) incidence countries (<100 cases/100,000/year), screening and preventive treatment (PT) for latent TB infection (LTBI) among people living with HIV (PLWH) is often recommended, yet guidelines advising which groups to prioritise for screening can be contradictory and implementation patchy. Evidence of LTBI screening cost-effectiveness may improve uptake and health outcomes at reasonable cost.

Methods: Our systematic review assessed cost-effectiveness estimates of LTBI screening/PT strategies among PLWH in lower TB incidence countries to identify model-driving inputs and methodological differences. Databases were searched 1980-2020. Studies including health economic evaluation of LTBI screening of PLWH in lower TB incidence countries (<100 cases/100,000/year) were included. Study quality was assessed using the CHEERS checklist.

Results: Of 2,644 articles screened, nine studies were included. Cost-effectiveness estimates of LTBI screening/PT for PLWH varied widely, with universal screening/PT found highly cost-effective by some studies, while only targeting to high-risk groups (such as those from...

**Discussion:** Cost-effectiveness studies of LTBI screening/PT for PLWH in lower TB incidence settings are scarce, with large variations in methods and assumptions used, target populations and screening/PT strategies evaluated. The limited evidence suggests LTBI screening/PT may be cost-effective for some PLWH groups but further research is required, particularly on strategies targeting screening/PT to PLWH at higher risk. Standardisation of model descriptions and results reporting could facilitate reliable comparisons between studies, particularly to identify those factors driving the wide disparity between cost-effectiveness estimates.

**Registration:** PROSPERO CRD42020166338 (18/03/2020).

**Keywords**
HIV; latent tuberculosis; screening; health economic; cost-effectiveness; cost-utility; model; review
Introduction

A quarter of the world’s population has latent TB infection (LTBI), meaning they are infected but do not (yet) have symptoms of tuberculosis (TB) and cannot transmit infection. Without antibiotics, approximately 5% of immunocompetent individuals acquiring LTBI progress to TB disease within the first two years following infection, and another 5% over the remainder of their lifetimes\(^1\). This risk is higher for people living with HIV (PLWH) and may remain elevated even with antiretroviral therapy (ART). While a 2010 systematic review estimated that approximately 30% of co-infected people may eventually develop TB disease, and these subjects were at increased risk of premature death\(^1\), a UK study found incidence of TB disease during long-term ART to be much closer to background rates\(^4\). It is therefore important to evaluate the costs and benefits of testing and treatment of LTBI for PLWH, yet little research has been published on the cost-effectiveness of LTBI screening and preventive treatment (PT, also referred to as chemoprophylaxis) for this group.

Earlier detection and PT of LTBI when patients are diagnosed with HIV or when they are receiving HIV care prevents progression to active disease, thereby reducing cost of TB care, TB-related morbidity and may also reduce onward TB transmission and costs of contact tracing. As well as these benefits to the patient and to the health system, treatment of patients with LTBI is also an important intervention for TB elimination, particularly for low-incidence countries where the long-lasting benefit of PT will not be mitigated by repeated TB re-exposure within the general population\(^5\). However, there is currently no consensus concerning which individuals to target for LTBI screening/PT: guidelines vary by low TB incidence country.

Many European countries test all HIV clinic attendees, either with the tuberculin skin test (TST) or interferon-gamma release assays (IGRA)\(^6\),\(^7\), while other countries favour a targeted approach. As TB incidence falls in low TB incidence settings, the contribution to active TB of those with reactivation of chronic latent infection increases, but the cost-effectiveness of LTBI screening/treatment falls. Targeting groups at higher risk of infection, for example migrants from endemic regions, may be more feasible and will maximise patient benefit while minimising government spending. For example, the British HIV Association (BHIVA) guidance advises testing with IGRA alone to all PLWH from high/medium TB incidence countries, and only screening those from low TB incidence countries (<40/100,000 population) if additional risk factors for TB are present (listed in the guidance)\(^8\). By contrast, the UK National Institute for Health and Care Excellence (NICE) recommends that all PLWH should be targeted for screening\(^9\). Given this divergence in guidelines, compliance is reported to be low\(^10\). A uniform, evidence-based national guideline for the UK is required.

We conducted a systematic review to evaluate whether health economic studies are comparable in their conclusions regarding the cost-effectiveness of LTBI screening/treatment for PLWH or targeting subpopulations of PLWH at higher risk of infection to improve this cost-effectiveness. We aimed to assess which aspects of these economic evaluations, in terms of both model structure and model inputs, most influence their predictions and where knowledge gaps remain, in order to guide future research to provide the necessary evidence on which to base national guidelines.

Methods

This study was registered on the International Prospective Register of Systematic Reviews (PROSPERO) registration number CRD42020166338 (18/03/2020). It was conducted in accordance with PRISMA guidelines\(^15\) (see Reporting guidelines\(^16\)).

Selection criteria

To be eligible for inclusion, studies had to:

1. Include an intervention involving screening for LTBI among PLWH aware of their HIV status, and subsequent LTBI diagnosis and treatment. PLWH may or may not be receiving antiretroviral therapy (ART).
2. Include scenarios for a lower TB incidence country (<100 cases/100,000/year).
3. Report results of a health economic evaluation employing a modelling component. This could include decision tree, Markov, individual-based models or any other type of health economic model structure. Analyses required a health component (e.g., quality-adjusted life-years (QALYs) gained/disability-adjusted life-years (DALYs) lost, deaths averted) and a cost component.

Studies were excluded where:

1. The study population was not exclusively PLWH.
2. The intervention involved mass LTBI chemoprophylaxis of all PLWH rather than treatment only following a positive LTBI screening test.
3. The intervention involved screening of TB disease rather than latent TB infection.

Articles for inclusion had to be literature (peer-reviewed full papers or research letters in peer-reviewed journals). Abstracts, presentations, posters, non-research letters and editorials were excluded (these formats provide insufficient details on methods used). Reviews and grey literature were also excluded. No restrictions were placed on the modelled study population in terms of factors such as age, gender, ethnicity, health or treatment status. There was no study exclusion based on choice of comparison groups, but their suitability was assessed as part of the evaluation of study quality. There were no restrictions by date or language of publication.

Search strategy and data extraction

We searched for published studies reporting the cost-effectiveness, cost-utility or cost-benefit of screening for LTBI among PLWH in lower TB incidence countries (defined as <100 cases per 100,000 population/year, WHO 2018 estimates\(^17\)). Ovid Embase, PubMed and Web of Science were searched for articles published between 1\(^{st}\) January 1980 and 30\(^{th}\)
September 2020 (date of the most recent search) using terms for cost-effectiveness studies, tuberculosis, screening and HIV (see Extended data\textsuperscript{16} for full search terms).

Two reviewers (RFB, CV) independently screened the papers at all levels: title, abstract and full-text. Discrepancies were discussed between the reviewers to reach a consensus, and where necessary, in consultation with co-authors. Bibliographies of articles passing the full-text screening were subsequently reviewed for any additional, relevant papers. A data extraction schedule was developed and used to retrieve information from included studies regarding aspects including: study characteristics (authors, publication year, conflicts of interest and funding statements), setting, characteristics of modelled population, interventions and comparators analysed, year/duration of study, data used for model inputs, model type (e.g., Markov, discrete event simulation), diagnosis methods (including sensitivity and specificity assumptions), latent and active TB positivity rates, LTBI reactivation rate, treatment uptake and completion rates, treatment effectiveness, health economic aspects including model time horizon, perspective adopted (e.g., health service, societal), health and cost discount rates applied, costs included (e.g., costs of screening, costs of treatment), health utilities, and the key results and conclusions of the study (e.g., total incremental costs, QALY/DALYs and incremental cost-effectiveness ratio (ICER) for each screening intervention). We extracted base case cost-effectiveness estimates plus other types of model outcome, and uncertainty bounds and sensitivity analysis methods. Data were extracted independently by two reviewers (RFB, CAD). For the purposes of this analysis, we did not contact authors for clarification because we aimed to evaluate the information that would be available to the reader, particularly policy and decision makers. All data were managed using a Microsoft Excel spreadsheet, and validated by an independent reviewer.

Data analysis
Included studies were summarised according to study design, comparators and overall results. Studies were compared and assessed on the basis of study quality, perspective, design and parameter selection and valuation. Study quality was assessed using the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement (RFB, CV).\textsuperscript{16} To aid comparability, costs were inflation-adjusted to 2018 in the local currency and then converted to US$ using consumer price indices and average annual exchange rates, using MS Excel version 2012\textsuperscript{20–21}. Forest plots were constructed using R version 4.0.3 to present study ICER (cost/QALY gained or cost/DALY averted) estimates. Cost-effectiveness studies may be more impactful by generating lower ICER values, so structural model assumptions which may particularly affect outputs, and therefore introduce bias, were evaluated. There were too few studies and lack of comparability between studies to employ further analysis by subgroup.

Results
Search results
Database searches identified 2644 titles to screen after removing duplicates, resulting in 17 articles that went to full-text review (Figure 1). Full-text review identified nine studies for inclusion and in-depth analysis\textsuperscript{22–30}.

Study characteristics
The main characteristics of included studies and the resulting ICERs are presented in Table 1 and epidemiological factors are summarised in Table 2. All studies were performed using dynamic-type Markov models with decision tree components except studies by Wong et al. (system dynamics model, similar to Markov)\textsuperscript{28} and Jo et al. (individual-based transmission model)\textsuperscript{30}. The target populations were in the US\textsuperscript{25,27,29}, Italy\textsuperscript{26}, Japan\textsuperscript{24}, Brazil\textsuperscript{27}, UK\textsuperscript{28,30}, and China (Hong Kong)\textsuperscript{28}. All studies included adult PLWH populations only, except Jo et al., where age-associated inclusion criteria were not recorded\textsuperscript{30}. Time horizons of lifetime\textsuperscript{29,29,30}, 30 years\textsuperscript{25,29,30}, 20 years\textsuperscript{25,29}, and 10 years\textsuperscript{30} were employed. All studies adopted a health service perspective except the study by Wong et al., which did not report the time horizon or perspective\textsuperscript{30}.

**LTBI screening strategies.** Four studies included screening comparisons between TST and IGRA tests\textsuperscript{24,25,27,30} and three evaluated testing schedules that involved both tests\textsuperscript{23,27,30}. The remainder evaluated TST only\textsuperscript{22,28}. PT regimens modelled were six-month\textsuperscript{22–24,30}, nine-month\textsuperscript{25,28}, and 12-month\textsuperscript{26–28} isoniazid, and isoniazid plus rifampent for three months\textsuperscript{27,29}. Capocci et al.\textsuperscript{20}’s analysis was informed by HIV clinical cohort data, where patients received six-month isoniazid or three-month isoniazid plus rifampin depending on drug interactions\textsuperscript{30}. Studies investigated a number of different screening strategies for a wide range of PLWH target populations (Table 1).

Counterfactuals were generally usual care (Azadi et al. used outcomes from public HIV care clinics not randomised to receive the LTBI screening/PT intervention\textsuperscript{24}; Wong et al., annual LTBI diagnoses taken from clinical data\textsuperscript{22}; Jo et al., baseline screening/PT levels previously estimated\textsuperscript{22,31} or zero testing\textsuperscript{23,28–27,30}; Kowada et al. evaluated screening/PT for HIV-infected pregnant women only, but did not compare strategies targeting screening/PT to different populations (close contacts, migrants from high TB burden countries, “occasional screenings”), keeping each analysis independent and comparing only costs and benefits for each test type used\textsuperscript{24}. The author used the most cost-effective testing strategy as the base case for each scenario, so all other ICER values presented were dominated.

One study specified that LTBI screening was undertaken at HIV diagnosis and annually thereafter\textsuperscript{28}; other studies modelled screening of populations in established HIV care\textsuperscript{22,23,29} or this was not recorded but is likely also to have been established care\textsuperscript{24–27}. Capocci et al.\textsuperscript{20} stated that the population on which their model was based was offered LTBI screening at their next routine appointment for those in established care, as well as all newly HIV-diagnosed patients\textsuperscript{30}.

**Screening and treatment parameters.** Two-thirds of studies did not report or incompletely reported test sensitivity and specificity values used\textsuperscript{22,23,26,28–30} (Table 2). For those studies reporting, TST sensitivity was 43–89% and specificity was 59–92%. IGRA sensitivity was 61%–83% while specificity was...
consistent at 98–99%. TST specificity is known to vary by BCG inoculation status, but only one study accounted for this (97% specificity for non-BCG-vaccinated individuals, 59% for vaccinated individuals\(^2\)). A further study stratified specificity by country of origin to reflect this difference implicitly (98% for US-born, 92% for non-US-born\(^3\)). The remaining study assumed 87% specificity\(^4\).

Assumed effectiveness of full-course PT with isoniazid (INH) for six months was 62–68\(^%\)\(^2\),\(^2\) (effectiveness assumptions

---

**Figure 1. Flow chart of study selection, showing included studies stratified by World Health Organization region.** The search identified 1627, 1261, and 791 potentially relevant titles from PubMed, Embase, Web of Science, respectively (3679 in total). Eight articles provided model-based cost-effectiveness estimates for the screening for and treatment of latent tuberculosis infection among people living with HIV in lower TB incidence countries and were included in the review. The search was conducted for articles published 1st January 1980 up to the 30\(^\text{th}\) September 2020. PLWH – people living with HIV; TB – tuberculosis. \(^1\) Higher TB incidence countries defined as \(\geq 150/100,000\) cases as of 2018\(^1\). \(^2\) Kowada et al. modelled "low TB incidence countries" but the majority of the input data are from Japan\(^2\).
Table 1. Summary of study characteristics of included economic evaluations of latent tuberculosis infection screening among people living with HIV in lower TB incidence countries. (Costs shown are in currencies and cost years as stated in the original publications.)

<table>
<thead>
<tr>
<th>Study (author, year)</th>
<th>Setting</th>
<th>Population screened</th>
<th>Intervention/alternatives</th>
<th>Model type</th>
<th>Perspective</th>
<th>Model horizon</th>
<th>Discount rate</th>
<th>Estimate year</th>
<th>WTP threshold assumed</th>
<th>Principal results</th>
<th>Conclusions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sawert et al. 1998</td>
<td>Italy</td>
<td>Hypothetical cohort of PLWH; 3 groups: 1) TST+, 2) anergic with various levels of immune suppression, 3) all PLWH</td>
<td>PT policy options: treating only: 1) TST+, 2a) TST+ and anergic with CD4 &lt;200 cells/mm³, 2b) TST+ and anergic with CD4 &lt;350 cells/mm³, 2c) TST+ and all anergic</td>
<td>Markov</td>
<td>Health service</td>
<td>10 years</td>
<td>3% per year</td>
<td>1997</td>
<td>NS</td>
<td>1) TST+: cost-saving (-US$7.7 million; 1153 [IQR 1026-1245] QALYs gained). Policies 2a-c increase life expectancy by extending PT to anergic patients and generally also lead to cost reduction.</td>
<td>PT for TST+ PLWH increases life expectancy and decreases medical costs. Its extension to anergic patients may be justifiable on economic grounds in populations with high TB prevalence</td>
</tr>
<tr>
<td>Linas et al. 2011</td>
<td>USA</td>
<td>PLWH</td>
<td>TST vs IGRA vs no screening</td>
<td>Markov</td>
<td>Health service</td>
<td>Lifetime</td>
<td>3% per year</td>
<td>2011</td>
<td>US$50,000 and US$100,000/ QALYG</td>
<td>TST vs no testing: US$12,800/QALYG; IGRA vs TST testing: US$23,800/QALYG</td>
<td>Screening should be prioritised for PLWH. IGRA is more cost-effective than TST screening</td>
</tr>
<tr>
<td>Kowada 2014</td>
<td>Low TB incidence countries</td>
<td>HIV-infected 20-year-old pregnant women</td>
<td>Different test scenarios: 1) TST, 2) QFT (IGRA), 3) T-Spot (IGRA), 4) TST followed by QFT, 5) TST followed by T-Spot</td>
<td>Markov</td>
<td>Health service</td>
<td>30 years</td>
<td>3% annual</td>
<td>2012</td>
<td>US$50,000/ QALYG</td>
<td>Base case (screening of close contacts): T-SPOT test was most cost-effective. TST followed by QFT were most cost-effective for screening of migrants and occasional screenings. (ICER values not stated)</td>
<td>IGRA recommended for TB screening of high-risk pregnant PLWH in low TB incidence countries</td>
</tr>
<tr>
<td>Azadi et al. 2014</td>
<td>Brazil</td>
<td>PLWH in Rio de Janeiro, at low risk of reinfection</td>
<td>PT of all TST+ PLWH with no signs of active TB vs usual care</td>
<td>Markov</td>
<td>Health service</td>
<td>1 year (interventions)</td>
<td>20 years (disease outcomes)</td>
<td>3% per year</td>
<td>2010</td>
<td>2010 Brazilian GDP per capita (US$11,700)</td>
<td>Intervention averts 1.14 discounted DALYs (1.57 undiscounted DALYs) per 100 people tested. Median ICER: US$2273 (IQR 1779-3135) per DALY averted (less than a quarter of Brazil's 2010 GDP)</td>
</tr>
<tr>
<td>Study (author, year)</td>
<td>Setting</td>
<td>Population screened</td>
<td>Intervention/alternatives</td>
<td>Model type</td>
<td>Perspective</td>
<td>Model horizon</td>
<td>Discount rate</td>
<td>WTP threshold assumed</td>
<td>Estimate year</td>
<td>Principal results</td>
<td>Conclusions</td>
</tr>
<tr>
<td>----------------------</td>
<td>----------</td>
<td>---------------------</td>
<td>--------------------------</td>
<td>------------</td>
<td>-------------</td>
<td>---------------</td>
<td>---------------</td>
<td>----------------------</td>
<td>---------------</td>
<td>------------------</td>
<td>----------------</td>
</tr>
<tr>
<td>Capocci et al. 2015†</td>
<td>UK</td>
<td>PLWH in London, ~1/3 originating from sub-Saharan Africa</td>
<td>Screening based on 1) NICE and 2) BHIVA guidelines, 3) all PLWH, 4) no testing (high incidence of missed cases with no testing compared with BHIVA and NICE testing)</td>
<td>Unclear</td>
<td>Health service lifetime</td>
<td>3.5% per year</td>
<td>2000-2005 ICER values: BHIVA vs no testing €2701/QALY (95%UI 1803-4607), NICE vs BHIVA testing: €698/QALY (95%UI 4130-11,813)</td>
<td>€24,000/QALY</td>
<td>2011/12</td>
<td>BHIVA and NICE testing regimens are cost-effective compared with no testing. Testing was cost-saving. Testing was cost-effective compared with alternative or more targeted TB testing strategies.</td>
<td></td>
</tr>
<tr>
<td>Tasillo 2017†</td>
<td>USA</td>
<td>Non US-born PLWH US residents</td>
<td>1) TST only, 2) IGRA only, 3) confirm positive (initial TST, IGRA confirmation for TST+), 4) confirm negative (initial IGRA, TST for all IGRA–, + on either test indicates LTBI)</td>
<td>Markov</td>
<td>Health service lifetime</td>
<td>3% per year</td>
<td>US$100,000/QALY</td>
<td>TST only: Dominated IGRA only: US$35,000/QALY Confirm positive: US$18,000/QALY Confirm negative: US$63,000/QALY</td>
<td>2015</td>
<td>Testing for and treating LTBI is cost-effective.</td>
<td></td>
</tr>
<tr>
<td>Wong et al. 2019†</td>
<td>China</td>
<td>PLWH in Hong Kong</td>
<td>Frequency of testing 1) zero, 2) testing by risk factors, 3) biennial testing (all PLWH), 4) up to 3 tests (all PLWH), 5) annual testing all PLWH (current policy)</td>
<td>System dynamics model</td>
<td>NR</td>
<td>NR</td>
<td>$50,000/QALY</td>
<td>$55,000/QALY</td>
<td>For PLWH testing LTBI negative at baseline, testing strategies were cost-effective. Most cost-effective testing strategies are likely to be cost-effective compared with current testing strategies under the assumed threshold.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Note: ICER = Incremental Cost-Effectiveness Ratio, LTBI = Latent Tuberculosis Infection, QALY = Quality Adjusted Life Year, TST = Tuberculin Skin Test, IGRA = Interferon Gamma Release Assay, PLWH = People Living with HIV.
### Study (author, year)
- **Jo et al. 2020**
- **Capocci et al. 2020**

### Setting
- **USA**
- **UK**

### Population screened
- PLWH in four states (California, Florida, New York, Texas)
- PLWH attending an ambulatory HIV clinic in London, UK

### Intervention/alternatives
- Rapid screening/PT scale-up of PLWH and other risk groups compared to baseline uptake rates.
- 30 testing strategies (including active TB only) based on test (IGRA, TST, CXR, induced sputum), BHIVA/NICE guidelines, targeting to subpopulations (Black Africans, middle TB incidence countries).

### Model type
- Individual-based TB transmission model
- Markov Health service

### Perspective
- Health service
- Other risk groups evaluated: non-US-born, diabetics, homeless, and incarcerated.

### Model horizon
- 30 years
- Lifetime

### Discount rate
- 3% per year
- 3.5% per year

### Estimate year
- 2018
- 2018/19

### WTP threshold assumed
- $6695/QALYG – California
- $2382/QALYG – Florida
- $1250/QALYG – New York
- $952/QALYG – Texas

### Principal results
- Only strategies testing PLWH (various IGRA, TST, CXR, induced sputum), BHIVA/NICE guidelines, targeting to sub-Saharan Africa or middle TB incidence countries, were cost-effective.
- No ICER threshold is stated but authors highlight in the sensitivity analysis scenarios which produce ICER values <$10,000/QALY gained.

### Conclusions
- Cost-effectiveness of screening/PT was highest for the PLWH risk group in all states.
- The policy of universal PT for PLWH i.e. no LTBI screening element and so was excluded from the review (Sawert et al. reported that policy 3 increased costs and may even decrease mean life exp.
- Majority of input data from Japan.
- Other risk groups evaluated: non-US-born, diabetics, homeless, and incarcerated.

---

### Notes
- **a** In all included studies the discount rate applied to both costs and benefits.
- **b** Policy 3 involved universal PT for PLWH i.e. no LTBI screening element and so was excluded from the review (Sawert et al. reported that policy 3 increased costs and may even decrease mean life exp.
- **c** No ICER threshold is stated but authors highlight in the sensitivity analysis scenarios which produce ICER values <$10,000/QALY gained.
- **d** Majority of input data from Japan.
- **e** Other risk groups evaluated: non-US-born, diabetics, homeless, and incarcerated.
- **f** Frequency schedule of occasional screening: scenario not defined.
- **g** High-risk women are those with known or suspected TB contacts, injection drug use, HIV infection, pregnancy, or residence in countries with TB incidence >40/100,000. This implies that all pregnant PLWH are high-risk.
- **h** System dynamics models are similar to Markov models in being cohort-based but allow interaction between different model entities e.g. infectious disease transmission models, where interactions between infected and uninfected individuals is important.
<table>
<thead>
<tr>
<th>Study (author, year)</th>
<th>Data sources</th>
<th>ART and MDR assumptions</th>
<th>LTBI prevalence*</th>
<th>Secondary TB transmission</th>
<th>Annual reactivation rate /active TB mortality</th>
<th>Test used (sensitivity, specificity)</th>
<th>Screening and PT uptake, adherence, completion</th>
<th>Adverse events</th>
<th>Utilities</th>
</tr>
</thead>
</table>
| Sawert et al. 1998²⁰ | Prospective cohort study, including cost data | Pre-ART setting 3-5% MDR - tx costs 10-fold higher | 6.6-21.1% | 10 new infections per untreated active TB case; 2 new infections per treated case | CD4 > 350: 2%/year  
CD4 200-350: 8%/year  
CD4 < 200: 12%/year  
Mortality:  
CD4 ≥ 200: 25%/year  
CD4 < 200: 36%/year | TST (NR, NR) | Screening uptake: NR  
75% PT adherence | INH 12mo  
No DILI: 85-95%  
Post DILI: 2.5% | DILI: 0.3-6.4% | Not reported¹ |
| Linas et al. 2011²⁵ | Published literature including CDC surveillance data and National Health and Nutrition Examination Survey for TST positivity rate | NR  
MDR not included | 5.3% (range 2-9%) | Each case of reactivation TB resulted in 0.31 (0.25-1.1) cases of secondary TB distributed throughout the expected lifetime of contact cases | 2.07%/year  
Mortality:  
5% risk (no comorbidities), 6% risk (other chronic conditions) over 6 months | TST (89% [50-100%], 98% US- and 92% non-US-born  
98% [50-100%]) | Screening uptake: NR  
80% PT adherence (IGRA) | INH 9mo  
Full course: 90% (75-100%)  
6-8mo: 60% (50-75%)  
3-5mo: 30% (0-69%) | DILI (<34y): 0.1%  
(0.05-0.15%)  
DILI (≥35y): 1%  
(0.5-1.5%)  
DILI mortality: 1%  
(0.5-1.5%) | LTBI state: 1  
INH tx without toxicity: 1 (0.9-1.0)  
Active TB state: 0.80 (0.6-1.0)  
Non-fatal DILI: 0.85 (0.6-1.0) (1 month)  
Month of TB or DILI death: 0.3 (0.2-0.5)  
After having active TB: 1.0 (0.9-1.0) |
| Kowada 2014²⁶ | Published literature | NR  
1.2% (0-10%) MDR - higher mortality and morbidity rates, >10-fold higher tx costs | 7-36% during pregnancy  
11-55% postpartum | Not included | 0.02-1.8%/year during pregnancy  
0.03-2.7%/year during postpartum  
Mortality:  
All-cause mortality: 0.00091 (20 years), 0.0013 (30 years), 0.0026 (40 years)  
Increased mortality due to active TB: 5.2 (95%CI 1.7-15.6)  
Mortality rate, MDR TB: 0.13 (95%CI 0.06-0.26) | TST (43%, 97% [non-BCG], 59% [BCG])  
IGRA (61% QFT 65% T-SPOT, 99% QFT 98% T-SPOT) | Screening uptake: NR  
80% PT adherence (IGRA)  
50% PT adherence (TST) | INH 6mo  
68%  
DILI: 1.1%  
Non-LTBI, non-TB: 1  
LTBI, no tx: 1  
LTBI, tx: no adverse events: 0.99  
LTBI, tx: DILI: 0.85 | Non-LTBI, non-TB: 1  
LTBI, no tx: 1  
LTBI, tx: no adverse events: 0.99  
LTBI, tx: DILI: 0.85  
Active TB, non-MDR (pre and during tx): 0.80 (no range)  
Active TB, MDR (pre and during tx): 0.58 (no range) |
<table>
<thead>
<tr>
<th>Study (author, year)</th>
<th>Data sources</th>
<th>ART and MDR assumptions</th>
<th>LTBI prevalence&lt;sup&gt;a&lt;/sup&gt;</th>
<th>Secondary TB transmission</th>
<th>Annual reactivation rate / active TB mortality</th>
<th>Test used (sensitivity, specificity)</th>
<th>Screening and PT uptake, adherence, completion</th>
<th>LTBI PT regimen and effectiveness&lt;sup&gt;b&lt;/sup&gt;</th>
<th>Adverse events</th>
<th>Utilities</th>
</tr>
</thead>
<tbody>
<tr>
<td>Azadi et al. 2014&lt;sup&gt;22&lt;/sup&gt;</td>
<td>Cluster-randomised trial 2005-2009 providing TST and IPT to PLWH in 29 HIV clinics in Rio de Janeiro (THRio study)</td>
<td>Majority (67%) of cohort on ART when initiating PT. Of the remainder, 35% initiated ART at some point during PT. MDR not included.</td>
<td>NR</td>
<td>Not included</td>
<td>4.8%/year&lt;sup&gt;c&lt;/sup&gt;</td>
<td>Mortality: 1.3 TB deaths over 20 years among 100 PLWH patients</td>
<td>TST (NR, NR)</td>
<td>NR</td>
<td>INH 6mo 87% effectiveness&lt;sup&gt;d&lt;/sup&gt;</td>
<td>Not included</td>
</tr>
<tr>
<td>Capocci et al. 2015&lt;sup&gt;23&lt;/sup&gt;</td>
<td>10 year follow-up data (2000-2010) from a large London, UK HIV clinical cohort</td>
<td>Model parameterised for 2000-2005 and 2005-2010 to reflect change in ART coverage in UK over time. ART coverage: 61% (2000), 74% (2005), 86% (2010).&lt;sup&gt;f&lt;/sup&gt; Effect of tx resistance implicitly explored in sensitivity analysis by varying PT effectiveness and tx costs.</td>
<td>Black Africans: 13% Middle TB incidence countries: 10% Low TB incidence countries: 3%</td>
<td>Not included</td>
<td>NR</td>
<td>Mortality: NR</td>
<td>TST (NR, NR)</td>
<td>IGRA (91% [70-100%], NR)</td>
<td>Screening uptake: 87% (87-100%) 87% (60-100%) PT uptake (remainder stated to have declined or failed to complete PT)</td>
<td>INH 6mo 62% (40-100%)</td>
</tr>
<tr>
<td>Tasillo et al. 2017&lt;sup&gt;27&lt;/sup&gt;</td>
<td>Published literature</td>
<td>NR</td>
<td>MDR not included</td>
<td>15.9% (range 0-100%)</td>
<td>Secondary infections (first generation only): 0.250 cases (0.1-1.0) (units not specified)</td>
<td>10% (range 5-20%) lifetime risk Mortality: 0.05 (range 0.025-0.075)</td>
<td>TST (67% [50-100%], 87% [50-100%]) IGRA (77% [50-100%], 99% [50-100%])</td>
<td>Screening uptake: NR return for TST result: 82% (0-100%) PT uptake: 90% (50-100%) PT completion: 78.3% (50-100%)</td>
<td>INH + rifapentine 3mo 90% (50-100%)</td>
<td>DILI: 0.5% (0.0-1.0) DILI mortality: 0.1% (0.0-0.2%)</td>
</tr>
<tr>
<td>Study (author, year)</td>
<td>Data sources</td>
<td>ART and MDR assumptions</td>
<td>LTBI prevalence</td>
<td>Secondary TB transmission</td>
<td>Annual reactivation rate /active TB mortality</td>
<td>Test used (sensitivity, specificity)</td>
<td>Screening and PT uptake, adherence, completion</td>
<td>LTBI PT regimen and effectiveness</td>
<td>Adverse events</td>
<td>Utilities</td>
</tr>
<tr>
<td>----------------------</td>
<td>--------------</td>
<td>-------------------------</td>
<td>-----------------</td>
<td>--------------------------</td>
<td>---------------------------------------------</td>
<td>------------------------------------</td>
<td>-----------------------------------------------</td>
<td>---------------------------------</td>
<td>--------------</td>
<td>----------</td>
</tr>
<tr>
<td>Wong et al. 2019&lt;sup&gt;28&lt;/sup&gt;</td>
<td>15-year longitudinal clinic data. Patients diagnosed 2002-2017</td>
<td>ART coverage varied in scenarios between baseline (80%) and 100%. 100% ART coverage assumed following active TB diagnosis. 1.6% MDR - higher morbidity, nearly 10-fold higher tx costs</td>
<td>26.2&lt;sup&gt;%&lt;/sup&gt;</td>
<td>Not included</td>
<td>Pre-ART: Non-locals: CD4 &lt;200: 39.1%/year Non-locals CD4 &gt;=200: 20.9%/year Locals CD4 &lt;200: 10.7%/year Locals CD4 &gt;=200: 7.9%/year On ART: Non-locals, CD4 &lt;200: 42.9%/year Non-locals CD4 &gt;=200: 9.1%/year Locals CD4 &lt;200: 9.5%/year Locals CD4 &gt;=200: 2.3%/year Mortality: 0.0001</td>
<td>TST (NR, NR)</td>
<td>LTBI screening uptake: 44-65% (first year) 39-66%/year (subsequent years) PT uptake: 44-76% (varied by study year)</td>
<td>INH 9mo Pre-ART: TB reactivation reduced to 0-0.0051 cases/py On ART: TB reactivation reduced to 0-0.0196 cases/py (range depends on CD4 count and locals vs non-local)&lt;sup&gt;b&lt;/sup&gt;</td>
<td>Not included</td>
<td>Without TB = 1&lt;sup&gt;u&lt;/sup&gt; Active TB, CD4 ≥200: 0.83 Active TB, CD4 &lt;200: 0.702 MDR-TB: 0.68</td>
</tr>
<tr>
<td>Jo et al. 2020&lt;sup&gt;29&lt;/sup&gt;</td>
<td>Published literature</td>
<td>Assumed PLWH population receiving ART MDR not included</td>
<td>Calibrated using national TB surveillance data stratified by state, ethnicity, age, and 5-year time periods</td>
<td>Transmission dynamic model. Average number of transmissions per active TB case calibrated to state-specific TB incidence (which decayed over time)</td>
<td>Calibrated using national TB surveillance data, assuming exponential decline in reactivation rate over time and higher rate with older age 9.2% active TB case fatality</td>
<td>IGRA (85%, NR)</td>
<td>Screening uptake: 100% PT uptake: 85% PT completion: 78%</td>
<td>INH + rifapentine 3mo 93%</td>
<td>3.2% without hospitalisation, 0.015% with hospitalisation</td>
<td>LTBI: 0.97 Active TB: 0.76 HIV state (assuming asymptomatic with ART): 0.94 PT toxicity (no hospitalisation): 0.75 PT Toxicity (hospitalisation): 0.5 QALY losses: Active (non-fatal) TBI: 0.12 Mean loss due to PT toxicity: 0.002</td>
</tr>
<tr>
<td>Study (author, year)</td>
<td>Data sources</td>
<td>ART and MDR assumptions</td>
<td>LTBI prevalence</td>
<td>Secondary TB transmission</td>
<td>Annual reactivation rate (active TB mortality)</td>
<td>Test used (sensitivity, specificity)</td>
<td>Screening and PT uptake, adherence, completion</td>
<td>LTBI PT regimen and effectiveness</td>
<td>Adverse events</td>
<td>Utilities</td>
</tr>
<tr>
<td>----------------------</td>
<td>--------------</td>
<td>-------------------------</td>
<td>----------------</td>
<td>--------------------------</td>
<td>-----------------------------------------------</td>
<td>-------------------------------------</td>
<td>---------------------------------------------</td>
<td>---------------------------------</td>
<td>----------------</td>
<td>----------</td>
</tr>
<tr>
<td>Capocci et al. 2020&lt;sup&gt;a&lt;/sup&gt;</td>
<td>HIV clinical cohort plus published literature</td>
<td>95% clinic population parameterising the model were on ART; BHIVA guidelines strategy based on duration of ART use MDR not included</td>
<td>9% tested subjects</td>
<td>0.2 secondary active TB cases prevented by averting each active case of TB (0.4, 1.0 and 2.0 explored in sensitivity analysis)</td>
<td>Lifetime risk of active TB: IGRA+: 10% TST+/IGRA–: 2% TST–/IGRA–: 0.02% (92) lifetime reactivation risk for PLWH in England and Wales) Mortality NR</td>
<td>TST (NR, NR) IGRA (NR, NR)</td>
<td>TST return rate for those having TSTs as well as IGRA: 53% (30-90%) PT uptake: 50% (35-65%) PT completion: NR</td>
<td>INH 6mo or INH + rifampicin 3mo 62% (59-65%)</td>
<td>Not included</td>
<td>Quality of life decrements: Active TB: 0.676 LTBI: 0.007 Tx asymptomatic active TB: 0.2</td>
</tr>
</tbody>
</table>

<sup>a</sup> Prevalence of LTBI among PLWH.

<sup>b</sup> Unless otherwise stated, effectiveness is of completed regimen.

<sup>c</sup> Calculated based on reported TB prevalence among tuberculin-positive, tuberculin-negative non-anergic and anergic patients.

<sup>d</sup> Non-adherers are assumed to be experience zero PT effectiveness and zero frequency of adverse events.

<sup>e</sup> Assumes DILI occurs on average during third month of preventive therapy.

<sup>f</sup> Sawert et al. 1998<sup>6</sup> state that they used “medians of recently published QoL adjustment factors for various levels of immunosuppression in HIV infection”<sup>67</sup>.

<sup>g</sup> Lower specificity for non-US-born due to Bacillus Calmette-Guérin (BCG) vaccination.

<sup>h</sup> No justification for large difference in adherence rates between TST-positive and IGRA-positive PLWH provided.

<sup>i</sup> No information on how adherence relates to PT effectiveness and adverse events.

<sup>j</sup> All states are amongst pregnant PLWH.

<sup>k</sup> Assuming 11.5 TB cases over 20 years among 100 PLWH patients (with 12% LTBI prevalence).

<sup>l</sup> Majority of PLHIV are not LTBI-infected; mortality of individuals with active TB not stated.

<sup>m</sup> An additional effect of PT reducing TB mortality (by 17%) in addition to reducing TB incidence was explored in sensitivity analysis.

<sup>n</sup> Assumed individuals experience the TB/HIV co-infected disability state for 1 year before reverting to the disability state of chronic HIV.

<sup>o</sup> In addition, for the scenario using BHIVA guidelines, LTBI testing is dependent on duration of ART use. Recommended LTBI testing for PLWH from sub Saharan Africa if duration on ART <2 years; from a middle TB incidence country and CD4 count <500 cells/mm<sup>3</sup> and duration on ART <2 years; and from a low TB incidence country and CD4 count <350 cells/mm<sup>3</sup> (23-fold reduction). On ART: Non-locals: reduced to zero for CD4 >=200 cells/mm<sup>3</sup>; reduced to 0.0051 cases/py for CD4 <200 cells/mm<sup>3</sup> (21-fold reduction). On ART: Locals CD4 <200 cells/mm<sup>3</sup>: 0.0025 (9-fold reduction).

<sup>p</sup> Suboptimal adherence is accounted for through lower estimates of PT effectiveness.

<sup>q</sup> As stated in the publication.

<sup>r</sup> No units stated.

<sup>s</sup> Wong et al. report that 26.2% of those tested for LTBI were positive among their cohort but LTBI prevalence reported for local and non-local PLWH populations in Supplementary Online Content does not tally with this.<sup>28</sup>

<sup>t</sup> Nonlocal infections are defined as “infections in non-Chinese individuals and residents without right of abode”.

<sup>u</sup> Utility = 1 for TB-uninfected PLHIV regardless of CD4 count.

<sup>v</sup> Stated as 0.25 in Jo et al.<sup>13</sup> but from review of the source publication, this represents the utility decrement rather than the utility weight.<sup>24</sup>

<sup>w</sup> Stated as 0.2% for patients testing TST– in the Supplementary Material<sup>39</sup>.

---

**ART** – antiretroviral therapy; **BCG** – Bacillus Calmette-Guérin; **BHIVA** – British HIV Association; **CBA** – cost-benefit analysis; **CD4** – CD4 count (cells/mm<sup>3</sup>); **CE** – cost-effectiveness; **CEA** – cost-effectiveness analysis; **CUA** – cost-utility analysis; **DILI** – drug-induced liver injury; **EE** – economic evaluation; **GDP** – Gross Domestic Product; **HIV+** – HIV-infected; **ICER** – incremental cost-effectiveness ratio; **IGRA** – interferon gamma release assay; **INH** – isoniazid; **LTBI** – latent tuberculosis infection; **MDR** – multidrug resistant; **mo** – months; **NR** – not reported; **OI** – opportunistic infection; **PT** – preventive therapy for LTBI; **py** – person-year; **TST** – tuberculin skin test; **tx** – treatment; **y** – years; **Z** – Pyrazinamide.

---

<sup>26</sup> Sawert et al. 1998.<sup>6</sup> Stated that they used “medians of recently published QoL adjustment factors for various levels of immunosuppression in HIV infection.”<sup>67</sup>

<sup>27</sup> Lower specificity for non-US-born due to Bacillus Calmette-Guérin (BCG) vaccination.

<sup>28</sup> No justification for large difference in adherence rates between TST-positive and IGRA-positive PLWH provided.

<sup>29</sup> No information on how adherence relates to PT effectiveness and adverse events.

<sup>30</sup> All states are among pregnant PLWH.

<sup>31</sup> Assuming 11.5 TB cases over 20 years among 100 PLWH patients (with 12% LTBI prevalence).

<sup>32</sup> Majority of PLHIV are not LTBI-infected; mortality of individuals with active TB not stated.

<sup>33</sup> An additional effect of PT reducing TB mortality (by 17%) in addition to reducing TB incidence was explored in sensitivity analysis.

<sup>34</sup> Assumed individuals experience the TB/HIV co-infected disability state for 1 year before reverting to the disability state of chronic HIV.

<sup>35</sup> In addition, for the scenario using BHIVA guidelines, LTBI testing is dependent on duration of ART use. Recommended LTBI testing for PLWH from sub Saharan Africa if duration on ART <2 years; from a middle TB incidence country and CD4 count <500 cells/mm<sup>3</sup> and duration on ART <2 years; and from a low TB incidence country and CD4 count <350 cells/mm<sup>3</sup> (23-fold reduction). On ART: Non-locals: reduced to zero for CD4 >=200 cells/mm<sup>3</sup>; reduced to 0.0051 cases/py for CD4 <200 cells/mm<sup>3</sup> (21-fold reduction). On ART: Locals CD4 <200 cells/mm<sup>3</sup>: 0.0025 (9-fold reduction).

<sup>36</sup> Suboptimal adherence is accounted for through lower estimates of PT effectiveness.

<sup>37</sup> As stated in the publication.

<sup>38</sup> No units stated.

<sup>39</sup> Wong et al. report that 26.2% of those tested for LTBI were positive among their cohort but LTBI prevalence reported for local and non-local PLWH populations in Supplementary Online Content does not tally with this.<sup>28</sup>

<sup>40</sup> Nonlocal infections are defined as “infections in non-Chinese individuals and residents without right of abode”.

<sup>41</sup> Utility = 1 for TB-uninfected PLHIV regardless of CD4 count.

<sup>42</sup> Stated as 0.25 in Jo et al.<sup>13</sup> but from review of the source publication, this represents the utility decrement rather than the utility weight.<sup>24</sup>

<sup>43</sup> Stated as 0.2% for patients testing TST– in the Supplementary Material<sup>39</sup>. 
were unclear in the study by Azadi et al.33), while nine-month effectiveness was assumed to be 90% for one study35, while a second study assumed differential effectiveness by CD4 count and region of origin (locals versus non-locals)36. Effectiveness of twelve-month INH and three-month INH + rifampicin were estimated as 85–95%36 and 90–93%37,38, respectively. Capocci et al. 2020 assumed 62% effectiveness for a cohort receiving either six-month INH or three-month INH + rifampicin, depending on drug interactions39.

PT adherence was reported heterogeneously. Some studies reported adherence levels (Sawert et al.26, Kowada et al. used different adherence levels depending on the test used29) while others reported PT uptake coverage and proportion completing the PT course25,27,29, but how adherence related to PT effectiveness and varied and was not always clear. For example, Sawert et al. assumed non-adherers had zero PT effectiveness and zero adverse events26. Linas et al. modelled PT effectiveness as a function of length of PT received (3–5, 6–8, full-course nine months) but did not state how their assumed 52% completion rate for PLWH translated into these lengths35. Kowada et al. assumed strikingly different PT adherence for PLWH using the IGRA (80%) and TST (50%) tests, without explanation for this difference or how this affected PT effectiveness40.

Adverse events were included by only five studies (Table 2) (drug-induced liver injury (DILI) only24–27, not specified by Jo et al.25). Adverse event prevalence ranged from 0.1% (Linas et al. <34-year PLWH34) to a range 0.3–6.4%.22, DILI-related mortality was accounted for in two studies (Linas et al. 1%,26, Tasillo et al. 0.1%)35 and a quality of life impact for four studies24,25,27,29 (utility values not reported by Sawert et al.26).

**Epidemiological parameters.** A wide range of LTBI prevalence estimates for the target populations were used, from 5.3% (PLWH in the US35) to a range as high as 11–55% (post-partum women in low TB incidence countries31) (Table 2). Jo et al. calibrated both LTBI prevalence and reaction rate of LTBI to TB disease using TB incidence data, with values not explicitly reported29. Reported reaction rates were also heterogeneous, with values of around 2%/year for PLWH with high CD4 counts in some studies24–26 and lifetime risk 10%37,38, to extremely large values of 8–21%/year even for PLWH at high CD4 counts8.

Secondary transmission was included in five of the nine studies25,27,29,30, all including only first generation transmission but assuming different transmission rates, with the exception of Jo et al., who employed a full TB transmission model25. Again, the model parameter, average number of transmissions per active TB case, was calibrated to state-specific TB incidence levels (which decayed over time), but values for this decline were not reported. TB-related mortality also varied considerably, being far lower in the ART era than rates assumed by Sawert et al. in the absence of ART8, although Jo et al. used a notably high 9.2% active TB case fatality25. Recording of these epidemiological parameters was incomplete for some studies22,23,30 (Table 2).

Three studies accounted for multi-drug resistance (MDR)24,26,28, all of which assumed around 10-fold higher treatment costs for active TB and two of which assumed higher morbidity and/or mortality24,28. In addition, Capocci et al. 2015 stated that they implicitly incorporated the impact of treatment resistance into their treatment effectiveness estimate23. Three studies did not explicitly incorporate ART (Table 2). ART use would be expected to reduce cost-effectiveness estimates; it reduces health benefits of the intervention because TB progression rates and active TB-related mortality is vastly reduced for PLWH on ART35. The one study parameterised based on the pre-ART era found LTBI screening/PT to be cost-saving26. In addition, HIV treatment and care costs continue for life; therefore, for PLWH whose lives are saved by preventing TB-related mortality, these costs continue to accrue over their lifetime. However, of the four studies explicitly incorporating the health impact of ART35,27,3,28, only one included HIV care/ART costs in their analysis37.

**Utility (quality of life) values.** All studies used QALYs as the principal health outcome measure except Azadi et al., who used DALYs for their study based on Brazil25. One study did not report utility values26. While some studies assumed LTBI had no impact on utility values for PLWH24,25,27, others assumed a small decrement25,29,30. TB disease was associated with a 0.17–0.20 utility decrement except for Azadi et al. (assumed a very small difference in disability weights between TB-HIV coinfected and HIV-infected individuals: 72.78 and 77.40, respectively25) and Capocci et al. (0.676 decrement35). Kowada et al. assumed a utility of 1 for all PLWH uninfected with TB, even for PLWH with low CD4 counts24. Other utility decrements included by some studies included adverse events34,25,27,29 and MDR24,28.

**Costs.** Key cost components are shown in Table 3. Despite adjusting for cost year, ranges for full-course LTBI PT ($103–1333), adverse event management ($289–12,987), TB disease treatment ($741–18,565) and per screening test (TST $8.28–46.51, IGRA $57.60–104.76) were large. Tasillo et al. included monthly healthcare costs for HIV ($2061, range $1030–3091) while three studies assumed 10-fold higher treatment costs for MDR TB)24,26,28. Capocci et al. 2020 included costs associated with asymptomatic, smear negative, culture positive TB ($1816)30 but full details of estimation were not reported.

**Main findings.** The diversity of model assumptions and parameter values only partly explain the diverse results from these studies. Figure 2 summarises the ICER estimates each included study reported for various LTBI screening/PT strategies, alongside willingness to pay (WTP) estimates commonly used. In general, studies found that at least one screening/PT strategy evaluated was cost-effective according to their setting-specific threshold (Figure 2 and Table 1) except Wong et al. because
they evaluated strategies for PLWH testing TST-negative at baseline\(^a\). Of the testing strategies evaluated, both Tasillo and Linas et al. concluded that strategies involving IGRA testing for PLWH were most cost-effective\(^{23,27}\). Capocci et al. 2015 concluded that for the UK, only strategies targeting LTBI screening to higher risk PLWH (as defined by NICE and BHIVA guidelines) were cost-effective in 2000–2005, but these strategies became more expensive (likely due to increased ART coverage and/or proportionally fewer PLWH from high TB incidence countries), so by 2005–2010 only the BHIVA targeting strategy (higher-risk PLWH defined by country of origin, CD4 count and ART duration) was cost-effective\(^b\). Their later paper included updated NICE guidelines and found that the most cost-effective strategies were not those based on UK guidelines, but involved targeting screening/PT to PLWH with country of origin in sub Saharan Africa and/or mid-high TB incidence countries\(^c\). In contrast, Jo et al. reported extremely favourable cost-effectiveness estimates for screening/PT to all PLWH in four US states\(^d\). Factors contributing to this large difference include the high TB disease case fatality assumed by Jo et al. (9.2\%) and the high cost of LTBI PT assumed by Capocci et al. (Table 3). Overall, the heterogeneity in model assumptions and parameter values we have described makes it difficult to make further comparisons between study estimates.

**Sensitivity analysis**

All studies provided a univariate (one-way) sensitivity analysis using a selection of model parameters, and all but one\(^e\) undertook probabilistic sensitivity analysis (PSA, where all or selected parameters are varied simultaneously within their parametric distribution to produce a range of plausible values for the ICER) (Table 5). However, choice and number of parameters included in analyses varied and were selected subjectively. Systematic presentation of the most influential parameters on model outcomes were attempted by four studies (as a table\(^{29,30}\) or as a Tornado plot\(^{29,30}\), albeit with only three parameters for Azadi et al.\(^{24}\)). PSA was generally used to create cost-effectiveness acceptability curves (CEACs) only in earlier studies, showing the strategies by WTP threshold, but more recent studies

---

**Table 3. Key cost components\(^a\) extracted from included studies (adjusted to 2018 USD\(^b\)).**

<table>
<thead>
<tr>
<th>Study (author, year)</th>
<th>Full-course LTBI chemoprophylaxis</th>
<th>Adverse event management</th>
<th>Active TB treatment</th>
<th>TST/IGRA testing</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sawert et al. 1998(^{26})</td>
<td>$357</td>
<td>$393(^c)</td>
<td>$7169</td>
<td>$10.22/NA</td>
</tr>
<tr>
<td>Linas et al. 2011(^{25})</td>
<td>$514</td>
<td>$289(^d)</td>
<td>$15,920</td>
<td>$46.51/$88.71</td>
</tr>
<tr>
<td>Kowada 2014(^{24})</td>
<td>$563</td>
<td>$12,987(^f)</td>
<td>$18,565(^f)</td>
<td>$16.80/$66.12</td>
</tr>
<tr>
<td>Azadi et al. 2014(^{22})</td>
<td>$103</td>
<td>Not included</td>
<td>$741</td>
<td>$31.92/NA</td>
</tr>
<tr>
<td>Capocci et al. 2015(^{23})</td>
<td>$1333</td>
<td>Unclear</td>
<td>$12,917</td>
<td>$27.36/$104.76</td>
</tr>
<tr>
<td>Tasillo et al. 2017(^{27})</td>
<td>$612</td>
<td>$354(^g)</td>
<td>$16,693(^g)</td>
<td>$8.28/$88.71</td>
</tr>
<tr>
<td>Wong et al. 2019(^{28})</td>
<td>$322</td>
<td>Not included</td>
<td>$12,245(^d)</td>
<td>$20.15/NA</td>
</tr>
<tr>
<td>Jo et al. 2020(^{29})</td>
<td>$394-451(^f)</td>
<td>$216-247(^f)</td>
<td>$10,574-22,565(^{19})</td>
<td>NA/$75-85(^c)</td>
</tr>
<tr>
<td>Capocci et al. 2020(^{30})</td>
<td>$969</td>
<td>Not included</td>
<td>$14,082</td>
<td>$26.95/77.64</td>
</tr>
</tbody>
</table>

IGRA – interferon gamma release assay; NA – not applicable (test not included in the analysis); Not included – cost of test not included in the analysis; TST – tuberculin skin test; tx – treatment.

\(^a\) List is not exhaustive.

\(^b\) Prices uplifted to 2018 US prices (most recent data) using the US Bureau of Economic Analysis (BEA) Price Index for Personal Consumption Expenditures by Function – Health\(^b\). Costs for Capocci et al. 2015\(^{27}\) were converted to Great British pounds using the exchange rate €1=£0.83 used in the publication, uplifted to 2018 UK prices using the UK Consumer Price Index of Health\(^b\), then converted to USD using the OECD purchasing power parity rate in 2018 (£0.687=US$1\(^{12}\)). Costs for Capocci et al. 2020\(^{30}\) were also converted to USD using the 2018 OECD purchasing power parity rate\(^b\).

\(^c\) Adverse events included were drug-induced liver injury (DILI) only for Sawert et al.,\(^{26}\) Linas et al.,\(^{25}\) Kowada et al.,\(^{24}\) and Tasillo et al.\(^{27}\) Sawert et al. assumed 10\% of DILI patients required hospitalisation\(^b\). Linas et al. assumed hospitalisation for fatal DILI cases (case fatality 1\%) but unclear what proportion of non-fatal DILI cases required hospitalisation\(^b\) – we have assumed 0\%. Tasillo et al. assumed excess costs for fatal DILI cases (case fatality 0.1\%)\(^d\); Jo et al. assumed 0.5\% of adverse events required hospitalisation\(^d\).

\(^d\) Average of costs to treat multidrug resistant (MDR) and non-MDR active TB.

\(^e\) Average of treatment for non-severe and severe (requiring hospitalisation) active TB.

\(^f\) Costs varied by US state.

\(^g\) Probability of hospitalisation with active TB assumed to be 49\%.

---
employed a more systematic, comprehensive approach to SA including presentation of ICER estimates with uncertainty intervals.

Quality assessment
Study quality varied considerably between studies (range 46–88% on CHEERS 25-point checklist, Table 4) with only...
<table>
<thead>
<tr>
<th>Item</th>
<th>Recommendation</th>
<th>Sawert 1998&lt;sup&gt;26&lt;/sup&gt;</th>
<th>Linas 2011&lt;sup&gt;23&lt;/sup&gt;</th>
<th>Kowada 2014&lt;sup&gt;24&lt;/sup&gt;</th>
<th>Azadi 2014&lt;sup&gt;22&lt;/sup&gt;</th>
<th>Capocci 2015&lt;sup&gt;21&lt;/sup&gt;</th>
<th>Tasillo 2017&lt;sup&gt;20&lt;/sup&gt;</th>
<th>Wong 2019&lt;sup&gt;28&lt;/sup&gt;</th>
<th>Jo 2020&lt;sup&gt;29&lt;/sup&gt;</th>
<th>Capocci 2020&lt;sup&gt;16&lt;/sup&gt;</th>
<th>Mean</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Title: Identify the study as an economic evaluation or use more specific terms such as &quot;cost-effectiveness analysis&quot;, and describe the interventions compared.</td>
<td>0 0</td>
<td>1</td>
<td>0.5</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>0.61</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>Abstract: Provide a structured summary of objectives, perspective, setting, methods (including study design and inputs), results (including base case and uncertainty analyses), and conclusions.</td>
<td>0.5</td>
<td>0.5</td>
<td>1</td>
<td>1</td>
<td>0.5</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>0.83</td>
<td></td>
</tr>
<tr>
<td>3a</td>
<td>Background and objectives: Provide an explicit statement of the broader context for the study.</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1.00</td>
<td></td>
</tr>
<tr>
<td>3b</td>
<td>Background and objectives: Present the study question and its relevance for health policy or practice decisions.</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>0.5</td>
<td>1</td>
<td>1</td>
<td>0.94</td>
</tr>
<tr>
<td>4</td>
<td>Target population and subgroups: Describe characteristics of the base case population and subgroups analysed, including why they were chosen.</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1.00</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>Setting and location: State relevant aspects of the system(s) in which the decision(s) need(s) to be made.</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1.00</td>
</tr>
<tr>
<td>6</td>
<td>Study perspective: Describe the perspective of the study and relate this to the costs being evaluated.</td>
<td>0.5</td>
<td>1</td>
<td>0.5</td>
<td>0.5</td>
<td>0.5</td>
<td>0.5</td>
<td>0</td>
<td>1</td>
<td>0.5</td>
<td>0.56</td>
</tr>
<tr>
<td>7</td>
<td>Comparators: Describe the interventions or strategies being compared and state why they were chosen.</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>0.5</td>
<td>0.72</td>
</tr>
<tr>
<td>8</td>
<td>State the time horizon(s) over which costs and consequences are being evaluated and say why appropriate&lt;sup&gt;1&lt;/sup&gt;</td>
<td>0.5</td>
<td>0.5</td>
<td>0.5</td>
<td>0.5</td>
<td>0.5</td>
<td>0.5</td>
<td>0</td>
<td>1</td>
<td>0.5</td>
<td>0.50</td>
</tr>
<tr>
<td>9</td>
<td>Report the choice of discount rate(s) used for costs and outcomes and say why appropriate.</td>
<td>1</td>
<td>1</td>
<td>0.5</td>
<td>0.5</td>
<td>1</td>
<td>1</td>
<td>0.5</td>
<td>1</td>
<td>1</td>
<td>0.83</td>
</tr>
<tr>
<td>10</td>
<td>Describe what health outcomes were used as the measure(s) of benefit in the evaluation and their relevance for the type of analysis performed.</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>0.94</td>
</tr>
<tr>
<td>11</td>
<td>Measurement of effectiveness: &lt;br&gt; Single study-based estimates: Describe fully the design features of the single effectiveness study and why the single study was a sufficient source of clinical effectiveness data. &lt;br&gt; Synthesis-based estimates: Describe fully the methods used for identification of included studies and synthesis of clinical effectiveness data.</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>0.5</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>------</td>
<td>----------------</td>
<td>-------------</td>
<td>------------</td>
<td>-------------</td>
<td>-------------</td>
<td>--------------</td>
<td>--------------</td>
<td>------------</td>
<td>----------</td>
<td>-------------</td>
<td>------</td>
</tr>
<tr>
<td>12</td>
<td>Measurement and valuation of preference-based outcomes: If applicable, describe the population and methods used to elicit preferences for outcomes.</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0.44</td>
</tr>
<tr>
<td>13</td>
<td>Estimating resources and costs: Describe approaches and data sources used to estimate resource use associated with model health states. Describe primary or secondary research methods for valuing each resource item in terms of its unit cost. Describe any adjustments made to approximate to opportunity costs.</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>0.5</td>
<td>0</td>
<td>0.5</td>
<td>0.5</td>
<td>0.5</td>
<td>0.44</td>
<td></td>
</tr>
<tr>
<td>14</td>
<td>Currency, price date, and conversion: Report the dates of the estimated resource quantities and unit costs. Describe methods for adjusting estimated unit costs to the year of reported costs if necessary. Describe methods for converting costs into a common currency base and the exchange rate.</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>0.5</td>
<td>1</td>
<td>1</td>
<td>0.94</td>
</tr>
<tr>
<td>15</td>
<td>Choice of model: Describe and give reasons for the specific type of decision-analytical model used. Providing a figure to show model structure is strongly recommended.</td>
<td>1</td>
<td>0.5</td>
<td>0.5</td>
<td>0.5</td>
<td>0</td>
<td>0.5</td>
<td>0.5</td>
<td>1</td>
<td>0</td>
<td>0.50</td>
</tr>
<tr>
<td>16</td>
<td>Assumptions: Describe all structural or other assumptions underpinning the decision-analytical model.</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>0.5</td>
<td>1</td>
<td>0</td>
<td>0.39</td>
</tr>
<tr>
<td>17</td>
<td>Analytical methods: Describe all analytical methods supporting the evaluation. This could include methods for dealing with skewed, missing, or censored data; extrapolation methods; methods for pooling data; approaches to validate or make adjustments (such as half cycle corrections) to a model; and methods for handling population heterogeneity and uncertainty.</td>
<td>0</td>
<td>1</td>
<td>0.5</td>
<td>0.5</td>
<td>0</td>
<td>1</td>
<td>0.5</td>
<td>0</td>
<td>0.5</td>
<td>0.44</td>
</tr>
<tr>
<td></td>
<td><strong>Results</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18</td>
<td>Study parameters: Report the values, ranges, references, and, if used, probability distributions for all parameters. Report reasons or sources for distributions used to represent uncertainty where appropriate. Providing a table to show the input values is strongly recommended.</td>
<td>0.5</td>
<td>1</td>
<td>0.5</td>
<td>0.5</td>
<td>0.5</td>
<td>1</td>
<td>0</td>
<td>0.5</td>
<td>0.5</td>
<td>0.56</td>
</tr>
<tr>
<td>19</td>
<td>Incremental costs and outcomes: For each intervention, report mean values for the main categories of estimated costs and outcomes of interest, as well as mean differences between the comparator groups. If applicable, report incremental cost-effectiveness ratios.</td>
<td>0</td>
<td>1</td>
<td>0.5</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>0.5</td>
<td>0.5</td>
<td>1</td>
<td>0.61</td>
</tr>
<tr>
<td>20</td>
<td>Characterising uncertainty: <em>Single study-based economic evaluation:</em> Describe the effects of sampling uncertainty for the estimated incremental cost and incremental effectiveness parameters, together with the impact of methodological assumptions (such as discount rate, study perspective). <em>Model-based economic evaluation:</em> Describe the effects on the results of uncertainty for all input parameters, and uncertainty related to the structure of the model and assumptions.</td>
<td>1</td>
<td>0.5</td>
<td>0</td>
<td>0.5</td>
<td>0</td>
<td>1</td>
<td>0.5</td>
<td>0</td>
<td>1</td>
<td>0.56</td>
</tr>
<tr>
<td>------</td>
<td>---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>-------------</td>
<td>------------</td>
<td>-------------</td>
<td>-------------</td>
<td>--------------</td>
<td>--------------</td>
<td>------------</td>
<td>----------</td>
<td>--------------</td>
<td>------</td>
</tr>
<tr>
<td>21</td>
<td>Characterising heterogeneity. If applicable, report differences in costs, outcomes, or cost-effectiveness that can be explained by variations between subgroups of patients with different baseline characteristics or other observed variability in effects that are not reducible by more information.</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>0.78</td>
</tr>
<tr>
<td></td>
<td><strong>Discussion</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>22</td>
<td>Study findings, limitations, generalisability and current knowledge: Summarise key study findings and describe how they support the conclusions reached. Discuss limitations and the generalisability of the findings and how the findings fit with current knowledge.</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>0.5</td>
<td>1</td>
<td>1</td>
<td>0.83</td>
</tr>
<tr>
<td></td>
<td><strong>Other</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>23</td>
<td>Source of funding: Describe how the study was funded and the role of the funder in the identification, design, conduct and reporting of the analysis. Describe other non-monetary sources of support.</td>
<td>0.5</td>
<td>0.5</td>
<td>1</td>
<td>0.5</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>0.72</td>
</tr>
<tr>
<td>24</td>
<td>Conflicts of interest: Describe any potential for conflict of interest of study contributors in accordance with journal policy. In the absence of a journal policy, we recommend authors comply with International Committee of Medical Journal Editors recommendations.</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>0.5</td>
<td>1</td>
<td>0.5b</td>
<td>1</td>
<td>1</td>
<td>0.78</td>
</tr>
<tr>
<td>Total</td>
<td></td>
<td>16.5</td>
<td>20.5</td>
<td>12.5</td>
<td>17.0</td>
<td>17.5</td>
<td>22.0</td>
<td>11.5</td>
<td>20.5</td>
<td>18.0</td>
<td>17.3</td>
</tr>
</tbody>
</table>

For each item, positive responses scored 1 and negative responses scored 0; intermediate scored 0.5. (24-item checklist; total points out of 25.)

a 0.5 score if time horizon is reported but with no justification.
b Conflict of interest stated.
### Table 5. Summary of sensitivity analyses employed in each included study (green cell = included in the analysis, red cell = not conducted/reported).

<table>
<thead>
<tr>
<th>Study (author, year)</th>
<th>One-way</th>
<th>Tornado plot</th>
<th>Two-way</th>
<th>PSA</th>
<th>Uncertainty bounds for results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sawert et al. 1998&lt;sup&gt;26&lt;/sup&gt;</td>
<td>Varied compliance only.</td>
<td>X</td>
<td>Varied compliance and LTBI prevalence for anergic and tuberculin+ PLWH</td>
<td>LTBI prevalence by TST result and anergy status, PT effectiveness, proportion experiencing DILI, DILI mortality rate, life expectancy by TB status and CD4 count</td>
<td>✓</td>
</tr>
<tr>
<td>Linas et al. 2011&lt;sup&gt;25&lt;/sup&gt;</td>
<td>Series of one-way and two-way sensitivity analyses; focus on uncertainty in rates of TB reactivation (using scenario analysis) and TST and IGRA test characteristics (specificity, sensitivity, cost). Other parameters explored: LTBI prevalence, treatment completion, long-term utility decrement for patients with cured TB, screening cost, proportion returning for TST result</td>
<td>X</td>
<td>Test specificity and sensitivity (TST vs IGRA)&lt;sup&gt;a&lt;/sup&gt;</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Kowada 2014&lt;sup&gt;24&lt;/sup&gt;</td>
<td>One-way SA found CE was sensitive to the sensitivity and specificity of various screening tests for the different screening scenarios. One-way SA used the following parameters: LTBI prevalence of PLWH during pregnancy; TB incidence of PLWH during pregnancy; LTBI prevalence of PLWH during postpartum period; TB incidence of PLWH during postpartum period; TB risk&lt;sup&gt;b&lt;/sup&gt; during pregnancy; TB risk&lt;sup&gt;b&lt;/sup&gt; in postpartum period; increased mortality due to active TB in pregnant PLWH; reactivation rate among pregnant PLWH by age group; prevalence of MDR-TB rate; mortality rate by MDR-TB; age-specific all-cause mortality for pregnant PLWH; probability of successful active TB treatment; probability of recurrence of active TB after treatment; effectiveness of PT; PT adherence for IGRA and TST; probability of DILI; sensitivity, specificity and costs of LTBI screening tests; all utilities</td>
<td>X</td>
<td>CEAC based on varying the parameters varied in one-way SA (graph not shown)</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Azadi et al. 2014&lt;sup&gt;21&lt;/sup&gt;</td>
<td>Clinical training costs, utility for TB-HIV coinfection, hazard ratio of TB death associated with the trial intervention (TST screening and PT)</td>
<td>✓</td>
<td>Clinical training costs, utility for TB-HIV coinfection, hazard ratio of TB death associated with the trial intervention (TST screening and PT)</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Capocci et al. 2015&lt;sup&gt;23&lt;/sup&gt;</td>
<td>Varied: costs of tests, costs of PT and active TB tx, QALY reductions for LTBI and active TB, IGRA sensitivity, screening and PT uptake, PT effectiveness, indeterminate IGRA rate</td>
<td>X</td>
<td>CEACs based on varying: costs of tests, costs of PT and active TB tx, QALY reductions for LTBI and active TB, IGRA sensitivity, screening and PT uptake, PT effectiveness, indeterminate IGRA rate, proportion of black Africans IGRA+, proportion of subjects from middle TB incidence countries IGRA+, proportion of subjects from low TB incidence countries IGRA&lt;sup&gt;+&lt;/sup&gt;</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Tasillo et al. 2017&lt;sup&gt;27&lt;/sup&gt;</td>
<td>Parameters varied included LTBI prevalence, test characteristics&lt;sup&gt;4&lt;/sup&gt;, age of cohort (which relates to remaining life expectancy and cumulative TB risk), quality-of-life estimates.</td>
<td>X</td>
<td>CEACs based on varying: reactivation rate, LTBI prevalence, test characteristics&lt;sup&gt;7&lt;/sup&gt;</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Study (author, year)</td>
<td>One-way</td>
<td>Tornado plot</td>
<td>Two-way</td>
<td>PSA</td>
<td>Uncertainty bounds for results</td>
</tr>
<tr>
<td>----------------------</td>
<td>---------</td>
<td>--------------</td>
<td>---------</td>
<td>-----</td>
<td>-------------------------------</td>
</tr>
<tr>
<td>Wong et al. 2019&lt;sup&gt;28&lt;/sup&gt;</td>
<td>Scenario analysis: varied levels of ART coverage and LTBI testing and treatment uptake.</td>
<td>X</td>
<td>Screening and PT coverage</td>
<td>CEACs based on varying: LTBI prevalence, PT effectiveness, LTBI test cost, PT cost, ART coverage, LTBI testing and PT coverage</td>
<td>X&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Jo et al. 2020&lt;sup&gt;29&lt;/sup&gt;</td>
<td>One-way SA to describe the association between each input variable and ICER. Results only presented for some high-risk groups and only for five input variables with biggest impact on ICER.</td>
<td>✓</td>
<td>X</td>
<td>CEACs and cost-effectiveness plane PSA plots based on varying a large number of parameters over specified distributions</td>
<td>✓&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>Capocci et al. 2020&lt;sup&gt;30&lt;/sup&gt;</td>
<td>One-way SA with halved and doubled cost for TST, T-Spot.TB, CXR, sputum induction, latent, asymptomatic, smear negative, culture positive and active TB treatment, transmission intensity, test uptake and quality of life parameters.</td>
<td>X&lt;sup&gt;c&lt;/sup&gt;</td>
<td>X</td>
<td>CEACs and uncertainty bounds for point estimates generated using parameters drawn from specified probability distributions</td>
<td>✓</td>
</tr>
</tbody>
</table>


<sup>a</sup> Linas et al. also varied IGRA test cost for various scenarios of TST test specificity.<sup>25</sup>

<sup>b</sup> Difference between “TB risk” and “TB incidence” not stated.

<sup>c</sup> Systematic one-way sensitivity analysis results presented as a table.

<sup>d</sup> “Test characteristics” not defined but includes at a minimum test sensitivity, specificity and proportion returning for TST result.

<sup>e</sup> 95% uncertainty interval presented for sensitivity analysis but not main results.

<sup>f</sup> Uncertainty bounds presented in manuscript text for Florida (US$282, range: cost-saving to US$11,000) and New York (US$11,265, range: cost-saving to US$119,000) only.
three studies scoring >80% and two studies scoring <60%. Particularly low-scoring items involved failure to justify model assumptions such as reasons for choice of time horizon, explanations of effectiveness and utility values used and full outlines of estimations of resources and costs. While only three points on the checklist are allotted to explanation of the model used, structural assumptions and analytical methods used (items 15–17), these are crucial to a proper understanding of how each analysis was undertaken, and scores for these items were low (mean 0.39–0.50 across studies). Lacking a complete appreciation of all model assumptions made it difficult to evaluate potential biases in study design. However, of the eight studies conducted in the ART era, only one included HIV care/ART costs in their analysis, which may push cost-effectiveness estimates up. Conversely, secondary transmission was included by only five studies, despite its incorporation driving estimates down.

Discussion

To our knowledge, this is the first systematic review of cost-effectiveness of LTBI screening/PT focussing on PLWH in lower TB incidence settings, and it highlights the limited number of studies published. Cost-effectiveness estimates of LTBI screening/PT for PLWH varied widely; taking studies published in the past five years, which should be relatively similar in terms of assumptions such as ART use, cost-effectiveness of strategies screening all PLWH varied from $2828 to $144,929 (n=5, 2018 prices). Included studies have such variation in strategies evaluated, target populations and methods and assumptions used, that it is hard for policy makers to interpret these results, identifying which model inputs are driving these extreme values and how they relate to their own populations, in order to make informed decisions regarding screening strategies. Strategies targeting screening/PT to PLWH at higher risk of LTBI were found to vary markedly in their cost-effectiveness (NICE 2016 strategy: $131,643/QALY gained, BHIVA 2011: $58,297/QALY gained in the UK), with alternative strategies found to be more cost-effective. These findings should be evaluated in conjunction with estimates of number of LTBI cases missed by each strategy in order to devise revised, coherent national guidelines.

Further research is required to provide the evidence base to inform LTBI screening policies. The many methodological facets listed in Table 1 and Table 2, which are not exhaustive, demonstrate the many factors contributing to study heterogeneity, with several study quality issues also identified. No study considered cost-effectiveness for children living with HIV. LTBI screening for newly HIV-diagnosed should be evaluated separately from catch-up programmes screening those in established HIV care, who are likely to have lower risk of LTBI. The most recent studies by Jo et al. and Capocci et al. 2020 come to very different conclusions, and while they are from different settings (US and UK), policy makers from all lower TB incidence settings need to understand the factors driving these differences to develop effective strategies for their own populations. Among these, the high TB mortality rate assumed by Jo et al. (9.2%) will drive ICER estimates down while the high cost of PT assumed by Capocci et al. 2020 will drive it up. However, TB mortality assumptions were not recorded by Capocci et al. 2020, and while Jo et al. fitted TB prevalence for the screened population to TB incidence data, prevalence estimates are not stated, so the reader cannot compare the two studies on many influential model inputs.

Capocci et al. 2015 demonstrated that cost-effectiveness of screening/PT strategies changed markedly over time. As LTBI prevalence is likely to reduce further with global TB prevention efforts, attention should focus on cost-effectiveness of targeting strategies to populations of PLWH at highest risk of infection and reflect on how cost-effectiveness may change over time as LTBI prevalence hopefully further decreases, as considered by Jo et al. However, LTBI screening/PT should not necessarily stop as its cost-effectiveness drops, as management of LTBI in high-risk groups including PLWH is a priority for TB control as part of the Global End TB Strategy. Furthermore, WTP thresholds vary hugely by country (Figure 2 illustrates the large differences in thresholds assumed by included studies), demonstrating the variation in what is deemed cost-effective, even when restricted to lower TB incidence settings.

While heterogeneity in model structure and assumptions can hamper comparability, it is still important to retain this diversity to explore the full range of uncertainty and identify which aspects, such as incorporating MDR, or onward TB transmission, are most influential and therefore important to include. However, a more standardised approach to presentation of methods and results, including systematic and well-justified sensitivity analyses, will facilitate comparisons between studies so that policy makers can fairly judge the evidence available on which to base LTBI screening guidelines in these settings. Items 15–17 of the CHEERS checklist, relating to model structure, assumptions and methods, only contribute three points to the quality score but should be given more weight as they are crucial to understand how all model inputs relate to the outputs. Lessons can be learned from other fields to develop a descriptive framework to make future cost-effectiveness analyses more rigorous and comparable.

Assessment of uncertainty is an important aspect of all cost-effectiveness analyses. We found sensitivity analyses conducted by included studies to be highly heterogeneous, and choice of parameters and the ranges through which they were varied were not always rigorously justified, though quality increased over time. To standardise the general reporting of cost-effectiveness analyses, the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) developed the CHEERS reporting checklist [28], which we used to evaluate study quality (Table 4). We recommend further standardisation of cost-effectiveness analyses to mandate inclusion of Tornado plots with justification of each parameter range used. These provide a more effective, objective summary of the most influential parameters driving model output (as long as parameter ranges are well justified) than lengthy descriptions of results in the text, and all parameters should be included rather than just a
selection, subjectively chosen (it is also important to identify which parameters have little impact on study outcomes as these should then have less weight in decision making). While PSA was widely used by included studies to create cost-effectiveness acceptability curves, we would endorse its use to generate uncertainty ranges for ICER estimates.

Improving clarity will further improve the accessibility of studies. We found a lack of precision in description of model parameters sometimes limited our understanding of how they related to model structure and in turn, model output. For example, authors should be clear whether “TB” refers to TB disease (often referred to as active TB) or latent TB infection, and should always specify units and clarify proportions versus percentages. They should state to which population group or subgroup the specific parameters apply, and for each subgroup created (e.g., patients developing DILI, those with MDR) it should be articulated: 1) what proportion of the cohort is in the subgroup, 2) over what duration they remain in this group and 3) how that affects their costs and health benefits. It should be clear, also, how inputs such as treatment adherence affect therapeutic effectiveness, and therefore influence model outputs.

A contentious issue regarding HIV-associated TB is the downstream costs of HIV care. ART is lifelong; therefore, interventions improving survival for PLWH may appear less cost-effective than for HIV-uninfected individuals. Therefore, it is perhaps unsurprising that only one included study accounted for HIV care costs41. Currently, PT for PLWH in low TB incidence (generally higher resource settings) has only a marginal gain in terms of life expectancy (PT nonetheless playing an important role in TB control by reducing morbidity, costs of TB disease treatment and onward TB transmission). Therefore, the inclusion or exclusion of ART costs should not be as influential as seen in other contexts40–42. Nonetheless, it raises important ethical questions regarding the design and interpretation of cost-effectiveness analyses involving increasing the life expectancy of PLWH40.

There are limitations to our analysis. Principally, we could not explore factors driving model output in more detail because of the limited number of studies included. While broadening our focus to include higher TB incidence countries would increase these numbers, the very different contexts (TB reinfection rates, mortality rates, ART coverage and costs, among others) means comparisons between studies would be equally challenging. We are also unable to rule out the possibility of publication bias, with potential selective publication of more favourable cost-effectiveness estimates. Only one of the included studies reported a conflict of interest of the authors (receiving personal fees from pharmaceutical manufacturers43), and selection/omission of model assumptions which would make outcomes more/less favourable (ART costs, secondary transmission) was not uniform across studies. However, Jo et al. selected the four states where more than half of US TB cases occur, so cost-effectiveness of screening is likely to be reduced in states with lower prevalence42. These states are also the richest in the US by Gross Domestic Product41.

Our study highlights the need for further research evaluating the cost-effectiveness of LTBI screening/PT, employing the highest standards of methods and reporting in order to make useful contributions to the field that can be used by policy makers to inform national guidelines. As TB prevalence hopefully continues to fall across the world, we need to consider targeting strategies which will be cost-effective now and in the future, to provide good value for the resources invested and better health for PLWH.

Data availability

Underlying data

All data underlying the results are available as part of the article and no additional source data are required.

Extended data


Reporting guidelines


Data are available under the terms of the Creative Commons Zero “No rights reserved” data waiver (CC0 1.0 Public domain dedication).

References


Page 23 of 23

Wellcome Open Research 2021, 6:51 Last updated: 09 MAR 2021